Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC

Following up on favorable data in 2017 on progression-free survival, a phase 3 trial on durvalumab validated its PFS benefit and added an overall survival benefit.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2Q50Vxt